In a phase 1b study, tarlatamab was evaluated using a subcutaneous dosing approach for extensive-stage small cell lung cancer. Investigators presented early safety and initial activity data from the DeLLphi-308 study at an IASLC conference, pointing to a potentially less burdensome administration route compared with intravenous schedules. The results come as small cell lung cancer continues to seek more tolerable delivery methods while maintaining efficacy. Subcutaneous administration may improve patient convenience, reduce infusion-center dependency, and support wider adoption if confirmatory trials uphold activity. For developers, early safety patterns in a new route are a critical gating factor, since delivery changes can affect exposure dynamics and adverse-event profiles. The update also positions tarlatamab within ongoing efforts to refine small-cell immunotherapy administration and dosing schedules.